6I
6IO.F Inogen Inc
- Market cap
- EUR 139M
- P/E
- -
- P/B
- 1.00x
- ROE
- -24.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6IO.F undervalued?
Graham numberThe Graham number of Inogen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inogen Inc fundamental analysis
No fundamental analysis for Inogen Inc yet.
Inogen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5…
Full company profileInogen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inogen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 203M | 249M | 358M | 362M | 308M | 358M | 377M | 316M | 336M | 349M | 343M |
| Gross Profit | 97.3M | 121M | 179M | 172M | 138M | 176M | 154M | 127M | 155M | 154M | 154M |
| Operating Income | 22.9M | 27.6M | 37.9M | 19.8M | -12.0M | 9.24M | -33.1M | -76.5M | -42.5M | -30.2M | -25.9M |
| EBITDA | - | 42.0M | 51.8M | 33.6M | 6.56M | 30.9M | -9.57M | -58.3M | -21.5M | -9.55M | -13.1M |
| Net Income | 20.5M | 21.0M | 51.8M | 21.0M | -5.83M | -6.33M | -83.8M | -102M | -35.9M | -22.7M | -37.8M |
| EPS | - | 1.00 | 2.38 | 0.95 | -0.26 | -0.28 | -3.65 | -4.47 | -1.51 | -0.84 | -1.44 |
| Balance Sheet | |||||||||||
| Total Assets | 214M | 275M | 376M | 447M | 462M | 490M | 405M | 326M | 296M | 299M | 265M |
| Total Liabilities | 32.0M | 48.0M | 65.5M | 103M | 112M | 119M | 108M | 121M | 122M | 106M | 108M |
| Shareholders' Equity | 182M | 227M | 310M | 345M | 350M | 370M | 297M | 205M | 174M | 192M | 157M |
| Cash & Short-term Investments | 92.9M | 143M | 197M | 198M | 212M | 236M | 187M | 125M | 114M | 104M | 81.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 31.0M | 60.5M | 60.0M | 40.6M | 37.0M | 23.6M | -37.5M | -3.23M | 5.91M | -11.2M | -10.9M |
| Capital Expenditure | 8.02M | 6.91M | 12.6M | 6.26M | 17.3M | 23.9M | 21.2M | 27.0M | 17.1M | 10.4M | 3.60M |
| Free Cash Flow | - | 50.3M | 47.0M | 34.1M | 19.4M | -434K | -58.8M | -30.2M | -11.2M | -21.6M | -12.5M |
| Ratios | |||||||||||
| ROE | 11.3% | 9.3% | 16.7% | 6.1% | -1.7% | -1.7% | -28.2% | -50.0% | -20.6% | -11.8% | -24.1% |
| ROA | 9.6% | 7.6% | 13.8% | 4.7% | -1.3% | -1.3% | -20.7% | -31.4% | -12.1% | -7.6% | -14.3% |
| Net Profit Margin | 10.1% | 8.4% | 14.5% | 5.8% | -1.9% | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% | -11.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Inogen Inc dividends
Inogen Inc has not paid dividends in the last 9 fiscal years.
Who owns Inogen Inc
- Insiders 13.21%
- Institutions 80.86%
- Public & others 5.93%
- Shares outstanding 26.0M
- Free float 22.7M
Inogen Inc company profile
- Company name
- Inogen Inc
- Ticker
- 6IO.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 753
- Fiscal year end
- December
- Address
- 500 Cummings Center, Beverly, MA, United States, 01915
- Phone
- 805 562 0500
- Website
- provider.inogen.com
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Inogen Inc management
1- Mr. Jason A. RichardsonCFO, Executive VP & Treasurer · born 1977